TY - JOUR
T1 - Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003
AU - Haas, Steven Joseph
AU - Hill, Richard
AU - Krum, Henry
AU - Liew, Danny Yearn Hian
AU - Tonkin, Andrew Maxwell
AU - Ioannides-Demos, Lisa L
AU - Stephan, Karen Lesley
AU - McNeil, John James
PY - 2007
Y1 - 2007
N2 - Background: Clozapine is an antipsychotic medication associated with a lower suicide rate compared with other antipsychotic agents. Clozapine is used specifically in patients for whom previous therapy was inadequate or not tolerated, and is the only antipsychotic agent associated with the development of myocarditis. Objective: To retrospectively review all adverse drug reaction reports voluntarily submitted to the Australian Adverse Drug Reactions Unit mentioning suspected myocarditis in clozapine-treated patients. Patients and methods: We accessed all electronic database entries and case reports citing suspected myocarditis associated with clozapine therapy from January 1993 through to December 2003, inclusive. Results: 116 case reports of suspected myocarditis amongst clozapine-treated patients were identified during the specified time frame (incidence between 0.7 and 1.2 of treated patients). Median patient age for these cases was 30 years (SD 11.1 years) compared with 37 years from the Clopine (R) registry. The condition developed within a median 16 days (mean 19.8 days; SD 17.3 days) of commencing clozapine for the bulk of patients developing myocarditis within 6 months (n = 93, 80.2 ). For all cases with known treatment commencement and cessation dates (n = 106), the condition developed within a median 17 days (mean 171.7 days, SD 530.9 days). Over nine-tenths of cases were prescribed clozapine within the dose range of 100 mg/day to 450 mg/day. Sixty patients (51.8 ) recovered from their episode when reported or during follow-up reports, whereas 17 patients (14.7 ) had not yet recovered: 27 patients (23.3 ) had unknown outcome when reported and the remaining 12 patients (10.3 ) died. Conclusion: Clozapine is uncommonly but importantly related to myocarditis, often fatal or near fatal and sometimes in relatively young patients with early onset after treatment initiation. The most striking feature about this condition is the wide diversity of nonspecific sympt
AB - Background: Clozapine is an antipsychotic medication associated with a lower suicide rate compared with other antipsychotic agents. Clozapine is used specifically in patients for whom previous therapy was inadequate or not tolerated, and is the only antipsychotic agent associated with the development of myocarditis. Objective: To retrospectively review all adverse drug reaction reports voluntarily submitted to the Australian Adverse Drug Reactions Unit mentioning suspected myocarditis in clozapine-treated patients. Patients and methods: We accessed all electronic database entries and case reports citing suspected myocarditis associated with clozapine therapy from January 1993 through to December 2003, inclusive. Results: 116 case reports of suspected myocarditis amongst clozapine-treated patients were identified during the specified time frame (incidence between 0.7 and 1.2 of treated patients). Median patient age for these cases was 30 years (SD 11.1 years) compared with 37 years from the Clopine (R) registry. The condition developed within a median 16 days (mean 19.8 days; SD 17.3 days) of commencing clozapine for the bulk of patients developing myocarditis within 6 months (n = 93, 80.2 ). For all cases with known treatment commencement and cessation dates (n = 106), the condition developed within a median 17 days (mean 171.7 days, SD 530.9 days). Over nine-tenths of cases were prescribed clozapine within the dose range of 100 mg/day to 450 mg/day. Sixty patients (51.8 ) recovered from their episode when reported or during follow-up reports, whereas 17 patients (14.7 ) had not yet recovered: 27 patients (23.3 ) had unknown outcome when reported and the remaining 12 patients (10.3 ) died. Conclusion: Clozapine is uncommonly but importantly related to myocarditis, often fatal or near fatal and sometimes in relatively young patients with early onset after treatment initiation. The most striking feature about this condition is the wide diversity of nonspecific sympt
UR - http://drugsafety.adisonline.com/pt/re/drs/toc.00002018-200730010-00000.htm;jsessionid=HWnZGwszQyh61XM9wnfBMWdm3byW0Zqx1J2gfzvJQGkY3RjtPJkZ!65375592!1
M3 - Article
SN - 0114-5916
VL - 30
SP - 47
EP - 57
JO - Drug Safety
JF - Drug Safety
IS - 1
ER -